Kangmei Pharmaceutical Co., Ltd. (SHA: 600518)
China flag China · Delayed Price · Currency is CNY
2.340
-0.020 (-0.85%)
Nov 18, 2024, 3:00 PM CST

Kangmei Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
5,1664,8274,1614,0545,26711,329
Upgrade
Other Revenue
47.347.318.9598.79144.52116.18
Upgrade
Revenue
5,2134,8744,1804,1535,41211,446
Upgrade
Revenue Growth (YoY)
4.43%16.60%0.67%-23.27%-52.72%-32.93%
Upgrade
Cost of Revenue
4,5484,1593,7494,06129,04610,498
Upgrade
Gross Profit
665.09715.07431.1491.52-23,634948.02
Upgrade
Selling, General & Admin
881.971,0151,0371,2832,0212,289
Upgrade
Research & Development
39.9445.6225.459.2711.36110.06
Upgrade
Other Operating Expenses
-306.7-312.48195.22653.49122.99218.78
Upgrade
Operating Expenses
387.46509.721,4713,1383,1582,652
Upgrade
Operating Income
277.63205.36-1,040-3,046-26,793-1,704
Upgrade
Interest Expense
-55.33-56.15-78.9-1,022-2,164-2,249
Upgrade
Interest & Investment Income
93.1275.1840.77194.062.17772.94
Upgrade
Currency Exchange Gain (Loss)
----0.02-0.2725.44
Upgrade
Other Non Operating Income (Expenses)
16.06-38.02-16.04-1,041-137.84-209.21
Upgrade
EBT Excluding Unusual Items
331.48186.36-1,095-4,915-29,093-3,364
Upgrade
Impairment of Goodwill
-----44.29-111.21
Upgrade
Gain (Loss) on Sale of Investments
-0.01-0.03---4.59-
Upgrade
Gain (Loss) on Sale of Assets
27.3619.610.9864.01-45.24-19.03
Upgrade
Asset Writedown
-100.94-99.69-307.46-2,634-1,424-476.61
Upgrade
Legal Settlements
-37.19-37.19-331.49-1,576-516.22-500
Upgrade
Other Unusual Items
41.3141.31-931.5817,21793.8579.57
Upgrade
Pretax Income
262.01110.37-2,6648,155-31,033-4,391
Upgrade
Income Tax Expense
3.796.829.75235.3962.55264.13
Upgrade
Earnings From Continuing Operations
258.22103.57-2,6947,920-31,096-4,655
Upgrade
Minority Interest in Earnings
-2.67-1.055.64-211.19-5.47
Upgrade
Net Income
255.55102.52-2,6887,918-31,085-4,661
Upgrade
Preferred Dividends & Other Adjustments
-----225
Upgrade
Net Income to Common
255.55102.52-2,6887,918-31,085-4,886
Upgrade
Shares Outstanding (Basic)
13,86410,25214,14813,89113,8154,937
Upgrade
Shares Outstanding (Diluted)
13,86410,25214,14813,89113,8154,937
Upgrade
Shares Change (YoY)
0.03%-27.54%1.85%0.55%179.83%-20.41%
Upgrade
EPS (Basic)
0.020.01-0.190.57-2.25-0.99
Upgrade
EPS (Diluted)
0.020.01-0.190.57-2.25-0.99
Upgrade
Free Cash Flow
-502.74-417.27-798.0842.58729.672,409
Upgrade
Free Cash Flow Per Share
-0.04-0.04-0.060.000.050.49
Upgrade
Gross Margin
12.76%14.67%10.31%2.20%-8.28%
Upgrade
Operating Margin
5.33%4.21%-24.89%-73.37%-495.06%-14.89%
Upgrade
Profit Margin
4.90%2.10%-64.31%190.68%-574.37%-42.69%
Upgrade
Free Cash Flow Margin
-9.64%-8.56%-19.09%1.03%13.48%21.05%
Upgrade
EBITDA
545.02490.98-730.42-2,493-26,148-1,009
Upgrade
EBITDA Margin
10.45%10.07%-17.47%-60.04%--8.82%
Upgrade
D&A For EBITDA
267.39285.62309.93553.19644.83695.14
Upgrade
EBIT
277.63205.36-1,040-3,046-26,793-1,704
Upgrade
EBIT Margin
5.33%4.21%-24.89%-73.36%--14.89%
Upgrade
Effective Tax Rate
1.45%6.16%-2.89%--
Upgrade
Revenue as Reported
5,2134,8744,1804,1535,41211,446
Upgrade
Advertising Expenses
-192.3114.0699.5259.46546.12
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.